-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
▎Editor of WuXi AppTec's content team today, Regeneron announced that its new crown neutralizing antibody combination therapy REGEN-COV (casirivimab+imdevimab) has reached the primary clinical endpoint in a phase 3 clinical trial for the prevention of new crown infection.
Among volunteers who received a subcutaneous injection of neutralizing antibody therapy, the risk of developing symptomatic COVID-19 was reduced by 81%.
It is worth mentioning that the previous neutralizing antibody therapy usually used intravenous infusion, and subcutaneous injection provided convenience for the treatment of patients.
In addition, REGEN-COV also reached the primary endpoint in a phase 3 clinical trial for the treatment of asymptomatic patients with neocoronavirus infection.
In the phase 3 clinical trial called 2069A, a total of 1,505 volunteers who were not infected by the new crown virus participated in the trial.
Some of their family members tested positive for the new crown virus within 4 days.
These volunteers received a subcutaneous injection of REGEN-COV or a placebo.
The results of the trial showed that a single dose of REGEN-COV reduced the participants' risk of developing symptomatic COVID-19 by 81% (p<0.
0001).
In the clinical trial named 2069B, 204 COVID-19 patients who tested positive for the new coronavirus but did not show symptoms received a dose of REGEN-COV or a placebo in the clinical trial created by WuXi AppTec's content team.
These patients did not detect antiviral antibodies in their bodies at baseline.
The results of the trial showed that a dose of REGEN-COV treatment reduced the risk of turning these asymptomatic patients into symptomatic COVID-19 patients by 31%, reaching the primary endpoint of the trial.
At the same time, this trial also showed that REGEN-COV shortened the duration of symptoms in patients by an average of 45%, and significantly reduced the virus levels in patients.
Dr.
George D.
Yancopoulos, President and Chief Scientific Officer of Regeneron, said that these studies show that subcutaneous injection of REGEN-COV neutralizing antibody therapy can provide immediate protection for people who have not been vaccinated, and is a convenient way to treat asymptomatic patients who are not hospitalized.
, Can change the development process of the disease.
Reference: [1] PHASE 3 PREVENTION TRIAL SHOWED 81% REDUCED RISK OF SYMPTOMATIC SARS-COV-2 INFECTIONS WITH SUBCUTANEOUS ADMINISTRATION OF REGEN-COV™ (CASIRIVIMAB WITH IMDEVIMAB).
Retrieved April 12, 2021, from https://investor.
regeneron.
com/news-releases/news-release-details/phase-3-prevention-trial-showed-81-reduced-risk-symptomatic-sars[2] PHASE 3 TREATMENT TRIAL IN RECENTLY INFECTED ASYMPTOMATIC PATIENTS SHOWED REGEN-COV™ (CASIRIVIMAB WITH IMDEVIMAB) SIGNIFICANTLY REDUCED PROGRESSION TO SYMPTOMATIC COVID-19.
Retrieved April 12, 2021, from https://investor.
regeneron.
com/news-releases/news-release-details/phase-3-treatment-trial-recently -infected-asymptomatic-patients Note: This article aims to introduce the progress of medical and health research, not a treatment plan recommendation.If you need guidance on treatment plans, please go to a regular hospital for treatment.
Among volunteers who received a subcutaneous injection of neutralizing antibody therapy, the risk of developing symptomatic COVID-19 was reduced by 81%.
It is worth mentioning that the previous neutralizing antibody therapy usually used intravenous infusion, and subcutaneous injection provided convenience for the treatment of patients.
In addition, REGEN-COV also reached the primary endpoint in a phase 3 clinical trial for the treatment of asymptomatic patients with neocoronavirus infection.
In the phase 3 clinical trial called 2069A, a total of 1,505 volunteers who were not infected by the new crown virus participated in the trial.
Some of their family members tested positive for the new crown virus within 4 days.
These volunteers received a subcutaneous injection of REGEN-COV or a placebo.
The results of the trial showed that a single dose of REGEN-COV reduced the participants' risk of developing symptomatic COVID-19 by 81% (p<0.
0001).
In the clinical trial named 2069B, 204 COVID-19 patients who tested positive for the new coronavirus but did not show symptoms received a dose of REGEN-COV or a placebo in the clinical trial created by WuXi AppTec's content team.
These patients did not detect antiviral antibodies in their bodies at baseline.
The results of the trial showed that a dose of REGEN-COV treatment reduced the risk of turning these asymptomatic patients into symptomatic COVID-19 patients by 31%, reaching the primary endpoint of the trial.
At the same time, this trial also showed that REGEN-COV shortened the duration of symptoms in patients by an average of 45%, and significantly reduced the virus levels in patients.
Dr.
George D.
Yancopoulos, President and Chief Scientific Officer of Regeneron, said that these studies show that subcutaneous injection of REGEN-COV neutralizing antibody therapy can provide immediate protection for people who have not been vaccinated, and is a convenient way to treat asymptomatic patients who are not hospitalized.
, Can change the development process of the disease.
Reference: [1] PHASE 3 PREVENTION TRIAL SHOWED 81% REDUCED RISK OF SYMPTOMATIC SARS-COV-2 INFECTIONS WITH SUBCUTANEOUS ADMINISTRATION OF REGEN-COV™ (CASIRIVIMAB WITH IMDEVIMAB).
Retrieved April 12, 2021, from https://investor.
regeneron.
com/news-releases/news-release-details/phase-3-prevention-trial-showed-81-reduced-risk-symptomatic-sars[2] PHASE 3 TREATMENT TRIAL IN RECENTLY INFECTED ASYMPTOMATIC PATIENTS SHOWED REGEN-COV™ (CASIRIVIMAB WITH IMDEVIMAB) SIGNIFICANTLY REDUCED PROGRESSION TO SYMPTOMATIC COVID-19.
Retrieved April 12, 2021, from https://investor.
regeneron.
com/news-releases/news-release-details/phase-3-treatment-trial-recently -infected-asymptomatic-patients Note: This article aims to introduce the progress of medical and health research, not a treatment plan recommendation.If you need guidance on treatment plans, please go to a regular hospital for treatment.
